Ann: Appendix 4C June 2018 Quarter, page-68

Hi Desco,

Not interested in trying to convince them of it, and I think old Steverino is keen to dry up the hc chatter about whatever obj says - by the simple expedient of saying less!

Have some sympathy with just getting on with business and telling us material things when they occur, perhaps indicative of hitting r&d transition point.

That said, a goals/ plan from the new Chair and a status report on whatever obj tech projects are still aiming for commercialisation seems a pretty reasonable expectation.

After appointing new Chair seems a timely juncture to me, but, won't be crying if it isn't until annual report time.

What I would most appreciate, whenever it is provided, is the clearest possible exposition of where obj is at with everything P&G and non-P&G and good old 'Bodywhatever' in particular.

I'm happy they are maintaining good cash-burn and relations with P&G, and they have no mfr, transport, etc. costs in deriving P&G revenue.

Now we have more BOD costs, expended to obtain the relevant skills, let's see some validation of why they are relevant and the effect of their application - in particular pertaining to some form of 'product commercialisation progress report'.

That's the central game - how about a report card?

Hygeine - dormant, probably dead
Masks - flying,
Tech 2 - product design, prototype mfr by obj planned for (date) consumer trial/ acceptance by client (quarter), commercialisation - unknown, stall fees payable?

Etc.